Results 61 to 70 of about 8,428 (249)

Case Report of a Rapidly Progressive Indolent T‐Cell Lymphoma of the Gastrointestinal Tract

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Indolent T‐cell lymphoma of the gastrointestinal tract (iTCL‐GI) is a relatively newly recognized disease entity. iTCL‐GI was first proposed by Perry et al. in 2013, before it was formally incorporated as a distinct disease category in the fifth edition of the World Health Organization Classification of Hematolymphoid Tumors: Lymphoid ...
Keitaro Shibuya, Akiko Tamura, Daiki Yafuso, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Toshimitsu Fujii, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
wiley   +1 more source

Differential diagnosis problem of pulmonary changes in ulcerative colitis [PDF]

Vojnosanitetski Pregled, 2010
Introduction. Inflammatory intestinal diseases are often accompanied with extraintestinal and even pulmonary manifestations. The treatment of these intestinal diseases includes sulphasalazine and mesalazine, which may have undesirable allergic and other ...
Đurić Mirna, Považan Đorđe, Sečen Svetozar, Jović Jelena   +3 more
doaj   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Clinical Pharmacology: Advances and Applications, 2012
Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and ...
Nanda K, Moss AC
doaj  

Randomized Controlled Trial on the Effectiveness of a Telehealth Gamification App for Self‐Management in Patients With Inflammatory Bowel Disease

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Inflammatory bowel diseases (IBDs) are chronic, relapsing‐remitting disorders that significantly impair quality of life and increase healthcare utilization. Although effective therapies are available, suboptimal adherence and insufficient monitoring often compromise disease control.
Narges Norouzkhani, Mahbobeh Faramarzi, Ali Bahari, Javad Shokri Shirvani, Hamed Tabesh   +4 more
wiley   +1 more source

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini, Hassan Valadbeigi, Seyedeh Mahdieh Khoshnazar, Saeed Khoshnood, Shahab Falahi, Delsuz Rezaee, Ali Hematian, Mohammad Hossein Haddadi   +7 more
wiley   +1 more source

Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review [PDF]

, 2023
Yurianna Santos, Arturo P Jaramillo
openalex   +1 more source

Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First‐Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background With guidelines recommending earlier advanced therapy (AT) use after 5‐ASA failure for patients with moderately‐to‐severely active ulcerative colitis (UC), it is important to explore treatment preferences at the point of escalation to first‐line AT.
Stefan Schreiber, Alissa Walsh, Peter Hur, Laura Panattoni, Brett Hauber, Natalie Land, Josh Coulter, Grace Gahlon, Karolina Wosik, Joseph C. Cappelleri, Melissa Culhane Maravic, Xiang Guo, Anthony Buisson   +12 more
wiley   +1 more source

Simple and sensitive spectrophotometric methods for the analysis of mesalamine in bulk and tablet dosage forms

Química Nova, 2011
Three simple, sensitive, economical and reproducible spectrophotometric methods (A, B and C) are described for determination of mesalamine in pure drug as well as in tablet dosage forms. Method A is based on the reduction of tungstate and/or molybdate in
Bala Sekaran Chandra, Siva Santhosh Bhogela, Manjusha Shaik, Chaitanya Sravanthi Vadlamudi, Meghana Chappa, Naga Sirisha Maddirala   +5 more
doaj   +1 more source

The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation

, 2017
Mesalamine serves as the gold standard in treating ulcerative colitis. However, its precise mechanism(s) of action remains unclear. Here, we show that mesalamine treatment rapidly decreases polyphosphate levels in diverse bacteria, including members of ...
Bazopoulou, D., Hasler, W.L., Young, V.B., Sun, D., Beaufay, F., Baker, J.R., Dahl, J.-U., Gray, M.J., Wang, Y., Koenigsknecht, M.J., Jakob, U., Lempart, J.   +11 more
core   +1 more source